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Background: Malaria causes significant mortality and morbidity in sub-Saharan Africa (SSA), especially among
children less than five years of age (U5 children). Although the economic burden of malaria in this region has been
assessed previously, the extent and variation of this burden remains unclear. This study aimed to estimate the
economic costs of malaria in U5 children in three countries (Ghana, Tanzania and Kenya).
Methods: Health system and household costs previously estimated were integrated with costs associated with
co-morbidities, complications and productivity losses due to death. Several models were developed to estimate the
expected treatment cost per episode per child, across different age groups, by level of severity and with or without
controlling for treatment-seeking behaviour. Total annual costs (2009) were calculated by multiplying the treatment
cost per episode according to severity by the number of episodes. Annual health system prevention costs were
added to this estimate.
Results: Household and health system costs per malaria episode ranged from approximately US$ 5 for non-
complicated malaria in Tanzania to US$ 288 for cerebral malaria with neurological sequelae in Kenya. On average,
up to 55% of these costs in Ghana and Tanzania and 70% in Kenya were assumed by the household, and of these
costs 46% in Ghana and 85% in Tanzania and Kenya were indirect costs. Expected values of potential future
earnings (in thousands) lost due to premature death of children aged 0–1 and 1–4 years were US$ 11.8 and
US$ 13.8 in Ghana, US$ 6.9 and US$ 8.1 in Tanzania, and US$ 7.6 and US$ 8.9 in Kenya, respectively. The expected
treatment costs per episode per child ranged from a minimum of US$ 1.29 for children aged 2–11 months in
Tanzania to a maximum of US$ 22.9 for children aged 0–24 months in Kenya. The total annual costs (in millions)
were estimated at US$ 37.8, US$ 131.9 and US$ 109.0 nationwide in Ghana, Tanzania and Kenya and included
average treatment costs per case of US$ 11.99, US$ 6.79 and US$ 20.54, respectively.
Conclusion: This study provides important insight into the economic burden of malaria in SSA that may assist
policy makers when designing future malaria control interventions.
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Despite a declining trend in the number of cases and
deaths over the last few years, malaria still causes signifi-
cant mortality and morbidity worldwide [1]. According
to the World Health Organization (WHO), approxi-
mately 225 million cases of malaria were estimated to
have occurred worldwide in 2009, leading to 781,000
deaths. Ninety one percent (~709,000 deaths) of these
deaths occurred in the African region [1]. The bulk of
the burden of malaria is observed in children under five
years of age (U5 children). In sub-Saharan Africa (SSA),
the severity of the disease in this age group is evident,
with malaria attacks leading to one million cases of cere-
bral malaria and four million cases of severe anemia
each year. Among the children with clinical attacks of
malaria, several thousand were estimated to have experi-
enced neurological damage and up to 250,000 have de-
velopmental problems [2].
In the context of increasing attention towards im-
proved malaria control in settings with budget con-
straints, competing health problems and weak health
systems [3], it is essential to provide policy makers with
relevant economic evidence of the economic benefits of
health care control and prevention strategies under dif-
ferent conditions and scenarios [4,5]. This information
can guide the introduction of new preventative mea-
sures, improve current strategies for malaria control and
help to design the scaling up of both new and old effica-
cious interventions.
Previous cost studies have reported the economic bur-
den of malaria to households and to the health system in
SSA, but the extent and variation of this impact remains
unclear. Household costs for malaria treatment, in par-
ticular indirect costs, are not adequately explored due to
difficulties in collecting and estimating these data [6-8].
Furthermore, while a lot of attention has focused on
both household and health system costs of uncom-
plicated malaria, there is limited knowledge of the eco-
nomic impact of severe cases, its consequences and
co-morbidities [9].
Various factors affect the economic burden of malaria
among children in endemic areas, including: treatment-
seeking behaviour [10], age of child [11] and epidemio-
logical conditions [12]. Despite this complexity, studies
of the economic burden of malaria generally estimate
average costs or cost distributions for an episode and
the effects of epidemiological, behavioural or clinical fac-
tors are rarely explored in association with costs [9].
The overall aim of this study was to estimate the eco-
nomic burden of malaria in U5 from the household and
health system perspectives in three selected SSA coun-
tries. Specific objectives were to estimate: (i) the costs of
treatment per malaria episode by severity and presence
of co-morbidities and clinical complications; (ii) theexpected treatment cost per episode per child; (iii) and
third, the annual economic costs of malaria, including
both prevention and treatment costs.
Methods
Three countries were selected to provide estimates for
different epidemiological settings within the SSA region:
Ghana, Tanzania and Kenya. Ghana is a West African
country with about 23 million inhabitants, presenting high
malaria endemicity, with 100% of the population living in
high transmission areas. Tanzania, with almost 42 million
inhabitants including Zanzibar, is an East African country
with moderate malaria endemicity. Almost three quarters
(73%) of the population in Tanzania live in high transmis-
sion areas and approximately one quarter in areas of low
transmission. Kenya is another East African country with
relatively low malaria endemicity. Kenya has more than 39
million inhabitants with 36% of the population living in
high transmission areas, 40% in low transmission areas,
and 24% in malaria-free zones [13].
Cost estimates
The costs of treating uncomplicated (outpatients without
co-morbidities) and hospitalized cases (all cases requiring
parenteral treatment, despite WHO case definitions for se-
vere malaria) were based in each of the three countries on
earlier studies that evaluated the economics of intermit-
tent preventive treatment of malaria in infants (IPTi) and
in children (IPTc) [14,15]. In IPTi study, data were col-
lected at different health facilities representing the three
levels of health care i.e. primary, secondary and tertiary
care in each country. Household costs were collected
through surveys from a sample of carers of approximately
300 children after an outpatient visit or at discharge (150
outpatients and 150 inpatients) in Kenya and Tanzania.
Data collection in Ghana included 207 outpatients and 10
inpatients cases interviewed at home [15]. Household
costs were divided into direct and indirect. Direct costs
were then divided into the cost of the visit or hospi-
talization (including facilities and personnel) and the cost
of the resources used for treatment (tests and medica-
tions). Indirect costs included the carers’ reported prod-
uctivity loss for the entire episode of malaria. Health
provider treatment costs included both recurrent and cap-
ital costs attributable to malaria care in U5 children.
The breakdown of costs collected during the IPTi
study were updated to 2009 rates using the Consumer
Price Index of the USA [16] and combined treatment
costs for co-morbidities, such as anemia, cerebral mal-
aria and neurological sequelae. In addition, costs were
modified according to the new first-line treatment for
uncomplicated malaria introduced in recent years [arte-
misinin-based combination therapy (ACT)]. ACT costs
incurred by the households were taken from a recent
Sicuri et al. Malaria Journal 2013, 12:307 Page 3 of 14
http://www.malariajournal.com/content/12/1/307report [17]. International drug supplier prices were
used and augmented by 15% to include shipment costs
when drug costs were entirely borne by the health
system [18].
Standards of care and associated costs of co-morbidities
and complications were estimated based on interviews
with clinicians, health workers and managers of the mal-
aria control programme in the three countries.
In the current study, incremental costs associated with
treatment and care of co-morbidities and medium-term
consequences not included in the base estimates were
considered, for both the health system and the house-
hold. Health system additional costs were considered in
terms of incremental personnel effort and other re-
sources, such as the extra costs associated with the ad-
ministration of parenteral treatment compared to oral
therapies. Household additional costs were considered in
terms of incremental direct (user fees, transportation)
and indirect costs (additional value of time lost). Drug
costs were imputed to the health system or households
depending on national or local policies. Specific costs as-
sociated with severity of disease and the presence of
co-morbidities was: cost of blood transfusion (severe
anemia), cost of anti-seizure/anticonvulsant therapies
(cerebral malaria) and rehabilitation costs post-discharge
(neurological sequelae).
A live chicken was assumed to be the payment for trad-
itional treatment for one episode of malaria [19,20]. Insti-
tutional local market prices were used to estimate the
monetary value of such a payment [21]. Total costs for
treating a malaria episode were estimated for the following
categories: uncomplicated malaria, malaria hospitalization,
malaria hospitalization + severe anemia, cerebral malaria,
and cerebral malaria + neurological sequelae. Malaria
hospitalization refers to all inpatient cases, regardless of
being severe cases according to WHO definition. These
categories were based on the perceptions of clinicians and
health workers interviewed rather than on institutional
definitions. ‘Uncomplicated malaria’ included all malaria
cases (usually laboratory confirmed) where no hospi-
talization was required. ‘Cerebral malaria’ was generally
referred to as malaria hospitalization of children in deep
coma. Total costs were calculated by adding health sys-
tem and household costs and subtracting user fees paid
by the households for consultation or admission at
health facility.
The human capital approach was applied to estimate
the potential life-long productivity losses due to death.
This cost was represented, in each country, by the
present value of an annuity with instalment equal to the
institutional minimum wage in force, for the period de-
fined by adulthood (from 15 years) and life expectancy
[22,23]. The present value at the time of childhood
death, of future potential earnings for an individual(onset of work at 15 years of age) was calculated using
the following formula:
V ¼ R 1− 1þ ið Þ−n½ =if g  1þ ið Þ−m
R is the annual earning; n is the time (in years) be-
tween 15 years and life expectancy; i is the discount rate
(assumed to be 3%); m represents the number of years
between childhood death and 15 years of age. In the
model, death was assumed to occur either at 0–1 or 1–4
years of age. Life expectancies differ between these two
age groups [24].
Description of the models
Models were developed to estimate the expected treat-
ment cost per malaria episode per child by severity and
presence of co-morbidities and clinical complications,
from the household and health system perspectives.
Therefore, the result of each model is the expected value
of treatment cost per episode per child, including house-
hold and health system costs.
Probabilities of incurring a malaria episode were taken
from the results of previous clinical trials (Table 1)
where health outcomes were measured at health facil-
ities rather than within the community. Therefore, such
data may be biased towards more intensive users of
health services. In order to assess if treatment-seeking
behaviour would impact the results, two different types
of models were constructed. The two models are identi-
cal in structure except that the treatment-seeking behav-
iour for uncomplicated malaria was considered in model
type 1 but not in model type 2 (Figure 1). The models
start with the probability of experiencing at least one
episode of malaria, consider the probability of such an
episode becoming severe and conclude with the prob-
ability of the severe episodes (with and without co-
morbidities) resulting in sequelae or death. In model
type 1, episodes of non-complicated malaria are associ-
ated with different types of costs depending on the type
of treatment sought. No cost was applied when malaria
treatment was not sought.
Scenarios
The burden of malaria in children varies by age. There-
fore, several versions of the two model types were de-
veloped by age groups for which clinical incidence data
were available [40,41]. In order to account for different
epidemiological contexts, the models were used for
cost estimation in Ghana, Tanzania and Kenya separ-
ately. To represent intra-country epidemiological het-
erogeneity, data from different areas were used. The
two types of model were estimated for five age groups
in Ghana, three age groups in Kenya and four age
Table 1 Model inputs and main sources
Country and age
range
Clinical/Epidemiological data Treatment-seeking behaviour
UM MO SA CerM* CerM +
NS*
CFR No
treatment
Health
facility
Pharmacy/
shop
Traditional
treatment
Ghana
2-15 months 0.64-1
[25]
0.06
[25]
0.006
[25]
0.015
[25]
0.12-0.15 0.0141
[25]
0.3 0.545 0.15 0.005
16-24 months 0.33-0.65
[25]
0.03
[25]
0.003
[25]
0.02
[25]
0.12-0.15 0.0157
[25]
0-24 months 0.65-1
[26]
0.05
[27]
0.03
[26]
0.022-0.08
[28,29]
0.12-0.15 0.003**
3-18 months 0.84-1
[27]
0.05
[27]
0.44
[27]
0.022-0.08
[28,29]
0.12-0.15 0.003**
3-59 months 0.51-0.63
[30]
0.004
[30]
0.02
[30]
0.022-0.08
[28,29]
0.12-0.15 0.003**
Tanzania
2-12 months 0.49
[31]
0.04
[32]
0.13
[31]
0.022-0.08
[28,29]
0.12-0.15 0.0051** 0.26 0.62 0.1167 0.005
2-11 months 0.16-0.24
[32]
0.04
[32]
0.25
[32]
0.022-0.08
[28,29]
0.12-0.15 0.0051**
12-23 months 0.39-0.50
[32]
0.05
[32]
0.24
[32]
0.022-0.08
[28,29]
0.12-0.15 0.0051**
0-59 months 0.28
[33]
0.05
[32]
0.24
[32]
0.022-0.08
[28,29]
0.12-0.15 0.0051**
Kenya
0-12 months 0.14-1
[34]
0.21
[34]
0.23
[34]
0.022-0.08
[28,29]
0.12-0.15 0.0053** 0.32 0.45 0.224 0.0086
10-24 months 0.17-1
[34]
0.21
[34]
0.23
[34]
0.022-0.08
[28,29]
0.12-0.15 0.0053**
0-24 months 0.67-0.86
[35]
0.21
[34]
0.26
[35]
0.022-0.08
[28,29]
0.12-0.15 0.0053**
Notes: All clinical/epidemiological values represent probabilities. UM uncomplicated malaria, MO malaria hospitalization, SA severe anaemia, CerM cerebral malaria,
CerM + NS cerebral malaria and neurological sequelae, CFR case fatality rate: percentage of clinical cases with fatal outcome. *CerM represents the proportion of
hospitalizations clinically considered as cerebral malaria while CerM + NS the proportion of CerM with neurological sequelae. **Most CFR were calculated as average
ratios among number of malaria deaths in U5 children/number of malaria cases in U5 children taken from World Malaria Reports (from year 2000 up to 2009). Triangular
distributions were used when only one value is presented (assuming a range of 15% lower and higher). Uniform distributions were used where two values are
presented. Ranges for severe anemia were constructed based on Murphy et al. [36]. Main data sources on neurological sequelae were taken from Bassat et al. [28].
References for treatment-seeking behaviour are Demographic and Health surveys of each of the three countries [37-39]. Values are the percentage of people who
sought treatment among whom with fever in the two weeks previous the survey.
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were constructed.
Model inputs and sources
Table 1 summarizes parameters used to populate the
models (Figure 1), with their relative sources. The age-
specific probabilities of experiencing at least one episode
of malaria, the probability of hospitalization and of co-
morbidities or complications/sequelae were taken from
several different sources, including clinical trials for IPTi
and of Intermittent Preventive Treatment of malaria in
children (IPTc) [25-27,30-32,34]. Probabilities included
in the models were obtained by rates published as out-
comes of children in the control group of each trial con-
sidered, translated into yearly probabilities [42]. Case
fatality rates (CFR) were calculated as average ratios ofthe number of malaria deaths in U5 children to the num-
ber of malaria cases in U5 children reported in World Mal-
aria Reports (between 2000 and 2009), apart from the case
of Ghana (2–15 and 16–24 months children) for which
malaria death was included among trial outcomes [25].
Information on treatment-seeking behaviour for mal-
aria was taken from Demographic and Health Survey
(DHS) data bases (Standard DHS, Standard AIS – AIDS
indicator surveys - in the case of Tanzania) [37-39]. For
model type 1, Chi-square tests were performed to test
the presence of a statistically significant association be-
tween the age of the child and treatment choices.
Sensitivity analyses
Most of the variables used to populate the models were
taken from studies providing local information, with
Figure 1 Models to estimate expected malaria treatment costs per episode per child (U5) and with or without treatment seeking
behaviour (TSB) component.
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small rural areas in each country (Table 1, [14]). To test
the uncertainty around estimated mean values, sensi-
tivity analyses were conducted. More specifically, input
variables were assigned a range of possible values, to
generate a probability distribution. Triangular or uni-
form distributions were constructed with the estimates
of the current study being the most likely value, and the
minimum or the maximum being used as the compara-
tor value.
Values used as comparators for health system costs for
malaria treatment were WHO-choice cost estimates [43].For each country, comparator household costs for malaria
treatment were derived from different sources. For Ghana,
household costs, comparator costs were taken from
Asante et al. [44]. Household costs in Tanzania were taken
from Hutton et al. [45]. For Kenya, estimates from Chuma
et al. [46] were used as comparators for uncomplicated
case costs; Ayieko et al. [47] cost data were used to esti-
mate the costs of complicated cases.
Epidemiological data were also inserted as a probability
distribution by comparing estimates with values taken
from the World Malaria Report 2009 [13]. Monte Carlo
simulations were performed within the constructed ranges,
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TreeAge Software. 2008. TreeAge Pro 2008 (Tree Age
Software, Inc., Williamstown, MA, USA).
Annual cost estimates
As no age breakdown is reported in the World Malaria
Report 2010 [1], the total number of malaria cases oc-
curring in U5 children during the year 2009 in Ghana
and Tanzania was estimated by assuming the same pro-
portion between U5 cases and all-age cases published in
the World Malaria Report 2009 [13]. For Kenya, the
number of malaria cases occurring in U5 children was
assumed to be 40% of cases occurring across all ages
[48]. U5 malaria cases were grouped according to sever-
ity, using the same clinical/epidemiological data men-
tioned above (Table 1). Each unit cost per episode, for
households and the health system, was multiplied by the
number of cases grouped by severity. Death was in-
cluded in the household indirect cost calculation and the
value of one death was represented by the net present
value of future potential earnings. Total annual costs
were presented from both the households and the health
system perspectives. The proportion attributable to U5
children of total annual costs for prevention, from the
health system perspective (bed nets and indoor residual
spraying) and for the same year in each country, was
added to household and health system costs to yield total
annual costs [49,50]. The proportion of prevention costs
imputable to U5 children was calculated by multiplying
the total cost by the proportion of the total population
accounted for U5 children in each country (28%, 18% and
17% for Ghana, Tanzania and Kenya, respectively [51]).
Average treatment costs, including household and health
system, were calculated by dividing total costs (excluding
prevention) by the total number of cases.
Results
Costs per episode based on severity
Standards of care by country and the breakdown costs
based on severity are summarized in Tables 2 and 3, re-
spectively. Total costs per malaria episode (including
direct and indirect household costs and health system
costs) based on disease severity and the presence of
complication and co-morbidities ranged from US$ 7.99
to $ 229.24 in Ghana, from US$ 5.2 to $ 137.74 in
Tanzania, and from US$ 11.24 to $ 287.81 in Kenya
(Table 3, Figure 2).
Cost incurred by households
On average, up to 55% of the overall costs in Ghana and
Tanzania and 70% in Kenya were borne by households.
Most of household costs are made of indirect costs
(85%) in Tanzania and in Kenya while this proportion
falls to about half (46%) in Ghana. This pattern repeatsover different severity levels. In Ghana, households need
to support much more direct costs than in the two other
countries of the study due to more expensive treatment
and higher medical service costs, which include high
health personnel salary. In the case of cerebral malaria
with neurological sequelae households in Kenya have the
highest economic burden with large productivity losses.
Average indirect costs are higher in Kenya with close
to US$ 8 per uncomplicated episode. This figure falls to
US$ 1.26 in Ghana where the lower minimum wage in
force brings the productivity losses down. Unsurprisingly
indirect costs increase sharply for hospitalized cases and
cases with neurological sequelae for which follow-up is
required leading to the highest costs: US$ 70, US$ 90
and US$ 212 in Ghana, Tanzania and Kenya respectively
(Table 3).
Cost incurred by the health system
Health system costs per episode vary according to sever-
ity from US$ 2.89 to US$ 123 in Ghana, US$ 1.75 to
US$ 48 in Tanzania and US$ 2.77 to US$ 57 in Kenya.
Regardless of severity, Ghana health system costs are
higher than for the other two countries due to higher
personnel costs. Costs of hospitalized cases are about ten-
fold the cost of uncomplicated case and they increase sub-
stantially when severe anemia or neurological sequelae
occurs. Blood transfusion is an expensive procedure used
in the first case while frequent follow-up visits are neces-
sary in the latter case. Average treatment costs and length
of stay were similar for malaria-related hospitalization
with or without cerebral consequences.
Models
Across the three countries, there was no statistical sig-
nificance observed in the association between the age of
the child and the choice of treatment (χ2-p value > 0.05).
For this reason, the same proportion of non-severe cases
seeking treatment was assumed in the different treat-
ment options regardless of age.
In addition to treatment costs per episode of malaria
according to severity (Table 3), the price of a live chicken
(US$ 3.79 in Ghana, US$ 4.94 in Tanzania and US$ 5.70
in Kenya) was used as a proxy for traditional treatment
cost and the cost of ACT was used when seeking care at
the pharmacy [17]. To calculate potential productivity loss
due to death for age ranging from 0–1 and 1–4 years, age-
specific life expectancy values were used. Productivity
losses differed amongst the three countries and were US$
11,794 and US$ 13,814 in Ghana, US$ 6,856 and US$
8,066 in Tanzania, and US$ 7,554 and US$ 8,897 in Kenya
(Table 4). The higher figures for Ghana are due to a longer
life expectancy.
Results of the Monte Carlo simulations (Table 5) showed
that the mean expected malaria treatment cost per episode
Table 2 Summary of standards of care by country (year 2009)
Malaria
severity
Antimalarial drugs Other drugs (non-anti-malarial) Average
length of stay
Other treatments
Ghana
UM Artesunate-amodiaquine (80%);
artemether-lumefantrine (20%)
Paracetamol (100%); promethazine
(20%)
0 -
MO Quinine (100%) Paracetamol (100%); phenobarbital
(10%)
7 -
MO + SA Quinine (100%) Gentamicin (10%); cotrimoxazole (10%) 10 Iron supplementation (100%);
blood transfusion (50%)
CerM Quinine (80%); artemether lumefantrine
(20%)
Paracetamol (80%); hydrocortison (5%);
phenobarbital (50%)
7
CerM +
NS
Quinine (80%); artemether lumefantrine
(20%)
Paracetamol (80%); hydrocortison (5%);
phenobarbital (50%)
12 Rehabilitation visit every 10 days
for 1 year
Tanzania
UM Artesunate-Amodiaquine (75%); Quinine
(25%)
Paracetamol (100%); promethazine
(20%)
0 -
MO Quinine (100%) Paracetamol (100%) 7 -
MO + SA Quinine (100%) Gentamicin (10%); cotrimoxazole (10%) 7 Iron supplementation (100%);
blood transfusion (50%)
CerM Quinine (100%) Paracetamol (60%); phenobarbital
(30%)
7
CerM +
NS
Quinine (100%) Paracetamol (60%); phenobarbital
(30%)
10 Rehabilitation visit every 15 days
for 1 year
Kenya
UM Artesunate-amodiaquine (75%);
artemether-lumefantrine (25%)
Paracetamol (100%); promethazine
(20%)
0 -
MO Quinine (80%); artemether lumefantrine
(20%)
Paracetamol (100%); phenobarbital
(10%)
7 -
MO + SA Quinine (80%); artemether lumefantrine
(20%)
Gentamicin (10%); cotrimoxazole (10%) 9 Iron supplementation (100%);
blood transfusion (50%)
CerM Quinine (80%); artemether lumefantrine
(20%)
Paracetamol (70%); phenobarbital
(30%)
7
CerM +
NS
Quinine (80%); artemether lumefantrine
(20%)
Paracetamol (70%); hydrocortison (5%);
phenobarbital (30%)
10 Rehabilitation visit every 15 days
for 1 year
Notes: UM uncomplicated malaria, MO malaria hospitalization, SA severe anemia, CerM cerebral malaria, CerM + NS cerebral malaria and neurological sequelae.
In brackets, the proportion of cases receiving treatment.
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US$ 1.29 to US$ 5.47 in Tanzania, and US$ 13.57 to
US$ 22.88 in Kenya.
Finally, total annual economic costs for treatment and
prevention of malaria in U5 children for the year 2009
were (in millions) US$ 37.8 in Ghana; US$ 131.98 in
Tanzania; and US$ 109.04 in Kenya (Table 6). Of these
costs, household treatment costs were (in millions) US$
5.98, US$ 17.98 and US$ 45.23 for the three countries,
respectively. Prevention costs were (in millions) US$ 29,
US$ 104 and US$ 42, respectively. When considering
productivity loss due to premature death, these figures
increased to (in millions) US$ 66.97, US$ 290.57 and US
$ 250.71, respectively. The average cost of a malaria epi-
sode was estimated to reach US$ 12 in Ghana, US$ 6.8
in Tanzania and US$ 20.5 in Kenya when weighing unitcosts with the occurrences for each outcome but leaving
out the prevention costs and mortality-related product-
ivity loss (Table 6).
Discussion
In the current study, the economic costs of malaria in
three SSA countries with different levels of malaria en-
demicity were investigated. Costs associated with malaria
in U5 children in Ghana, Tanzania and Kenya was sub-
stantial, particularly when severity of the episode, co-
morbidities and medium term consequences were con-
sidered. National annual costs for the prevention and
treatment of malaria in U5 children corresponded to
0.14%, 0.62% and 0.36% of the Gross Domestic Product
(GDP) (year 2009) of Ghana, Tanzania and Kenya, re-
spectively [52].
Table 3 Total cost of one episode of malaria by severity
in 2009 US$
Household Health system total* costs
Malaria case Direct Indirect Total
Ghana
UM 4.44 1.26 5.70 2.89 7.99
MO 24.51 24.22 48.73 27.49 75.62
MO + SA 74.67 53.50 128.17 64.1 191.67
CerM 24.51 24.66 49.17 27.49 76.06
CerM + NS 36.75 70.20 106.95 122.89 229.24
Average 32.98 34.77 67.74 48.97 116.12
Tanzania
UM 0.42 3.14 3.56 1.75 5.2
MO 5.46 14.36 19.82 18.56 38.38
MO + SA 5.46 20 25.46 48.21 73.67
CerM 5.46 14.36 19.82 19.13 38.95
CerM + NS 7.86 89.72 97.58 40.16 137.74
Average 4.93 28.32 33.25 25.56 58.79
Kenya
UM 0.73 7.95 8.68 2.77 11.24
MO 10.88 21.4 32.28 20.86 51.89
MO + SA 10.88 35 45.88 54.26 96.57
CerM 10.88 21.4 32.28 20.86 51.89
CerM + NS 20 212.2 232.2 56.86 287.81
Average 10.67 59.59 70.26 31.12 99.88
Notes: UM uncomplicated malaria, MO malaria hospitalization, SA severe
anemia, CerM cerebral malaria, CerM + NS cerebral malaria and neurological
sequelae. *Total treatment costs = household direct + household indirect +
health system – user fees.
Figure 2 Total treatment costs according to severity.
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should lead to lower treatment cost, however, the rela-
tionship between the two variables is not usually
straightforward. Both prevention and treatment costs
were included in national annual costs of malaria to
represent the total cost for malaria. However, no con-
sideration was applied on their relationship, as this
goes beyond the scope of this study.
There were slight differences in the treatment of se-
vere and cerebral malaria [28]. In Ghana treatment was
different from Kenya and Tanzania for the use of hydro-
cortisone in 5% of cases classified as cerebral malaria.
When combining the cost for each severity level with
their probability of occurrence, the type 1 model esti-
mated lower costs than type 2 model. The first model
considers indeed a proportion of uncomplicated cases
not seeking treatment, therefore not generating any cost.
For each of the three countries the percentage of cases
of fever with no treatment was around 30% and conse-
quently a cost equal to zero had a strong impact on the
average total cost for malaria. The exception is Ghana
(2–15 months) where the price paid for ACT at the
pharmacy (U$ 1.37 on average, much higher than costs
incurred at public health facilities) has increased the
expected cost in model type 1.
Previously published data for Ghana reported the aver-
age costs for health care provider treatment and for
households (direct and indirect) to be around US$ 6.87
and US$ 15.79, respectively [44]. These are lower than
the estimates in the current study. Previous data from
2009 showed the mean cost of a malaria admission in
Kenya, from the provider perspective, was higher than
that estimated in the current study (US$ 95.58 vs. US$
Table 4 Other costs included in the models
Type of cost Life expectancy 2009 US$
Ghana
Productivity loss due to infant deaths* 56.6 11794.01
Potential productivity loss due to children death** 60.2 13814.85
Traditional treatment+ - 3.79
ACT median costs (median, interquartile range) - 1.37 [0.68, 2.40]
Tanzania
Productivity loss due to infant deaths* 50.3 6856.98
Potential productivity loss due to child death** 53.3 8066.92
Traditional treatment+ - 4.94
ACT median costs (median, interquartile range) - 0.70 [0.35, 2.15]
Kenya
Productivity loss due to infant deaths* 53.5 7554.08
Potential productivity loss due to child death** 57.1 8897.63
Traditional treatment+ - 5.70
ACT median costs (median, interquartile range) - 0.66 [0.53, 1.71]
Notes: *0-1 year; ** 1-4 years; +as a proxy, the cost of a live chicken was used; ACT Artemisinin Combination Therapy.
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[47]. In Tanzania, health provider costs were similar to
those estimated in this study, with previous estimates of
US$ 20.0 for the treatment of one episode of malaria
(combining outpatient and inpatient cases) and US$ 22.3
for one episode of severe anemia [53]. However, care
must be taken when comparing estimates from different
studies, since in this study, productivity loss due toTable 5 Expected treatment cost of a malaria episode by age
Expected
Country and
age range*
Model type 1 with TSB**
Mean Confidence interval Min
Ghan
2-15 months 22.3 11.7 40.48 8.11
3-24 months 10.65 7.2 14.77 5.78
0-24 months 15.31 8.35 26.32 6.31
16-24 months 8.34 5.26 12.48 4.2
3-59 months 5.45 3.26 8.38 2.7
Tanza
2-12 months 3.49 2.62 4.48 2.37
2-11 months 1.29 1.01 1.59 0.93
12-23 months 3.41 2.84 4 2.61
0-59 months 2.12 1.9 2.36 1.8
Keny
0-12 months 13.57 3.88 24.01 3.27
10-24 months 15.23 5.05 25.62 4.30
0-24 months 19.90 17.19 22.74 16.18
Notes: *References of input values used in Table 1; **TSB treatment-seeking behavipremature death was also considered and looked at a
variety of severity levels. Although direct comparisons
with other studies are not straightforward due to differ-
ent objectives and to different methodologies, this study
used previous estimates as comparator values in the sen-
sitivity analysis. This allowed us to control for uncer-
tainty of parameters used and for the potential intra-
country variability of costs [54].-group and model type (Monte Carlo simulation)
treatment cost (US$) 2009
Model type 2 without TSB**
Max Mean Confidence interval Min Max
a
54.16 20.42 14.38 28.38 12.45 32.71
16.85 15.25 10.43 21.43 8.75 25.93
36.83 16.79 10.5 25.64 8.42 36.09
14.22 10.94 2.58 16.52 5.49 19.17
10.45 8.47 5.27 12.74 4.69 15.24
nia
4.94 4.15 3.77 4.59 3.66 4.68
1.7 1.66 1.32 2.06 1.2 2.6
4.31 4.26 3.64 4.98 3.4 5.4
2.47 5.47 3.45 7.58 2.78 8.07
a
25.20 15.69 4.40 27.60 3.51 29.49
27.20 17.37 5.62 29.41 4.66 31.35
23.69 22.88 19.43 26.49 18.01 27.60
our.
Table 6 Annual economic costs (US$) for malaria treatment and prevention (for 2009)
Number
of casesa
Household
cost per
episodeb
Health system
cost per
episodec
Total
household
costs
Total health
system treatment
cost
Total cost Average
treatment cost
per case
Ghana
Uncomplicated malaria 721,827 5.70 2.89 4,114,412 2,086,079 6.200,492
Malaria hospitalization 36,091 48.73 27.49 1,758,731 992,151 2,750,882
Cerebral malaria 1,643 49.17 27.49 80,792 45,169 125,960
Sequelae 256 106.95 122.89 27,426 31,514 58,940
Death 2,279 12,804.43 29,187,094 29,187,094
Health system prevention costs 28,643,462
TOTAL including costs associated
with productivity loss due to death
35,168,455 66,966,829
TOTAL excluding costs associated
with productivity loss death
5,981,361 3,154,913 37,779,735 11.99
Tanzania
Uncomplicated malaria 3,979,828 3.56 1.75 14,168,187 6,964,699 21,132,886
Malaria hospitalization 178,155 19.82 18.56 3,531,024 3,306,549 6,837,573
Cerebral malaria 8,111 19.82 19.13 160,755 155,158 315,913
Sequelae 1,266 97.58 40.16 123,520 50,836 174,356
Death 21,254 7,461.95 158,592,785 158,592,785
Health system prevention costs 103,520,000
TOTAL including costs associated
with productivity loss due to death
176,576,271 290,573,513
TOTAL excluding costs associated
with productivity loss death
17,983,486 10,477,242 131,980,728 6.79
Kenya
Uncomplicated malaria 2,567,086 8.68 2.77 22,282,304 7,110,827 29,393,132
Malaria hospitalization 648,270 32.28 20.86 20,926,168 13,522,920 34,449,088
Cerebral malaria 29,513 32.28 20.86 952,691 615,649 1,568,340
Sequelae 4,606 232.20 56.86 1,069,544 261,905 1,331,448
Death 17,222 8,225.85 141,667,404 141,667,404
Health system prevention costs 42,300,000
TOTAL including costs associated
with productivity loss due to death
186,898,111 250,709,412
TOTAL excluding costs associated
with productivity loss death
45,230,707 21,511,301 109,042,008 20.54
Notes: aThe total number of malaria cases occurring in U5 children in 2009 was estimated for each country by assuming the same proportion of total cases
accounted for by U5 cases as published in the World Malaria Report 2010; b, csee Table 3.
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cases of severe malarial anemia incurred higher costs than
cases of cerebral malaria with no severe anemia. These
higher costs were due to blood transfusions. Among other
costs, the administration of blood transfusions increases
personnel costs. Personnel costs are also higher for cases
of cerebral malaria that result in neurological sequelae,
due to the rehabilitation/follow up of the children. From
the household perspective, the cost of an episode of cere-
bral malaria with neurological complications represented
30% of the GDP per capita in Kenya [55]. For each of thethree countries, direct household costs depend on whether
households incur the cost of drug treatment. One paradox
with drug treatment is that these costs are greater for un-
complicated malaria than for severe malaria because ACT,
which is used for the treatment of uncomplicated malaria,
is more expensive than quinine, which was the first-line
treatment for severe cases at the time of the study.
The method used for assessing productivity losses due
to premature death, the human capital approach, al-
though widely used has some limitations [22,55]. For in-
stance, this approach ignores other dimensions of illness
Sicuri et al. Malaria Journal 2013, 12:307 Page 11 of 14
http://www.malariajournal.com/content/12/1/307(such as pain and suffering) as well as non-market activ-
ities (such as loss of leisure) that may be as important to
individuals as economic loss. Another issue that needs
attention involves the choice of an appropriate social
discount rate to convert future earnings into present
values. Discount rate depends on risk aversion and on
time preferences: the use of acceptable values for these
parameters would imply further investigation that was
beyond the aim of this study. Therefore, these specific
productivity losses were reported separately.
The estimated productivity losses are substantial, espe-
cially considering that the GDP per capita in each of the
three countries studied is about US$ 2.0 per day [52].
Potential productivity losses were higher for older than
for younger children because of their longer life expect-
ancy. From an epidemiological point of view however,
the probability of being infected is higher in younger
than in older children. Results of the models highlighted
some compensation effect between these two factors.
Looking at expected costs per child, in the case of
Ghana, data could be easily compared between children
aged 2–15 months and children aged 16–24 months, as
epidemiological data were taken from the same clinical
trial. The higher productivity losses of older children
were compensated by the lower probability of infection,
which was equal to 0.64-1 for children aged 2–15
months and 0.33-0.65 for children aged 16–24 months,
as the CFR is very similar across the two age groups
[25]. For Kenya, a straightforward cost comparison could
be performed between children within the age ranges 0–
12 months and 10–24 months, as data from these age
groups were taken from the same clinical trial [34]. In
contrast to Ghana, expected malaria costs were higher
for older children (10–24 months) than for younger
children (0–12 months). In Kenya expected costs were
higher when children were followed up 0–24 months
due to the high probability of both clinical and severe
symptomatic malaria occurring during the clinical study
[35]. It is important to point out that variation across
age groups within the same country pick up also intra-
country epidemiological heterogeneity as nearly all in-
formation for the different age groups were taken from
different clinical trials.
Net present value of lifelong productivity losses was
used to represent the cost of premature patient death.
However, the major short-term cost following the death
of a person in SSA is the funeral. There is strong evi-
dence, at least for South Africa, to suggest that funeral
expenses have a substantial impact on household bud-
gets. In a recent study it was found that, on average,
households spend the equivalent of one year’s income
for a funeral for an adult [56].
During the last few years a national scheme of health
insurance has been introduced in Ghana [57]. In thisstudy, a scenario was considered in which no one had
health insurance and everyone had to pay for health care
in Ghana. However, it has been shown that health insur-
ance cardholders accounted for 7% of the population in
2005 and 45% of the population in 2008 [58]. Despite
this increase in health insurance coverage, the assump-
tion that households need to pay for health care may
only have a minor effect on results, as was reported in a
recent study that health insurance in Ghana had a posi-
tive and significant impact on utilization of health care
services but had no effect on out-of-pocket expenditure
[59]. Moreover, in Tanzania and Kenya health insurance
schemes exist, the adhesion to which is compulsory, re-
spectively, for public servants and for all salaried em-
ployees. However, the coverage of such schemes is low
in both countries and the impact on results should be
minor [60,61].
Results reported may underestimate true costs, espe-
cially for costs paid by the households, due to various fac-
tors. First, funeral costs were not considered because a
child’s funeral cost is unknown and there is no evidence to
suggest that out-of-pocket expenses for funeral of a child
are the same as for an adult. Second, treatment costs in-
curred by households may have also been underestimated.
There is evidence of “informal payments” being used to fa-
cilitate access to health care. Studies have shown that,
when informal payments are considered, the total cost for
malaria treatment may be three times higher than that
reported by health care providers [62-64]. Third, the cost
of traditional treatment may be far higher than the proxy
used in this study [65]. Fourth, annual household costs did
not include household prevention costs. These were not
collected during the IPTi study as surveys were under-
taken for children with malaria, which can be an import-
ant source of bias for estimation of prevention costs. Fifth,
although costs associated with severe anemia were esti-
mated and used in the models, as a conservative measure,
they were not included in the aggregate annual costs of
malaria due to the complex and unclear interaction be-
tween malaria and anemia [66]. A further source of under-
estimation may derive from diagnostic costs, included in
health system costs. As diagnostic cost estimates were in-
cluded in clinical studies, these all refer to blood smear
which may have a low incremental impact on total costs.
On the other hand, a source of overestimation of costs
may be the assumption that children with uncomplicated
malaria received ACT only at health facilities or at private
pharmacies. Although ACT was adopted as first-line its
actual level of use remains low [67]. The assumption was
necessary due to the absence of precise estimates of access
to ACT for the countries included in this study. The
WHO recently modified their recommendation, to include
ACT for treating severe malaria cases as well as uncompli-
cated malaria. This is expected to increase treatment costs.
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Malaria exerts a significant economic burden on health
care providers and households. Cost estimations for a sin-
gle malaria episode provide important information. How-
ever, it is fundamental to consider severity, co-morbidities
and, at least, medium-term consequences when estimating
the economic burden of malaria. Additional insights are
provided by examining how costs vary as a function of fac-
tors that affect the probability of incurring an infection.
The results of this study may help to guide the introduc-
tion of new prophylactic measures, to improve current
strategies for malaria control and to design the scaling up
of both new and old efficacious interventions.
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